Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Wyeth Continues Karo R&D Activities | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Wyeth Continues Karo R&D Activities

Wyeth has agreed to take on all of Karo Bio’s future R&D activities under the companies’ drug discovery collaboration, beginning September 1, 2009.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Wyeth has agreed to take on all of Karo Bio’s future R&D activities under the companies’ drug discovery collaboration, beginning September 1, 2009. The collaboration aims to identify and select development candidates for treatment of inflammatory diseases, focusing on the liver X receptor (LXR) as target receptor. The two companies entered the collaboration in 2001.

“We are pleased that this exciting LXR program continues within Wyeth. Since Wyeth will perform all future research and development, Karo Bio will not put any more internal resources into the project and will therefore not receive any further research funding from Wyeth. However, the Collaboration, Research and License Agreement between the companies shall remain in effect,” said Per Olof Wallström, president and chief executive officer of Karo Bio.

Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conference

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics